52 research outputs found
Dual abrogation of Mnk and mTOR; a novel therapeutic approach for the treatment of aggressive cancers
Targeting the translational machinery has emerged as a promising therapeutic option for cancer treatment. Cancer cells require elevated protein synthesis for cell growth and exhibit augmented activity to meet the increased metabolic demand. Eukaryotic translation initiation factor 4E (eIF4E) is necessary for mRNA translation, its availability and phosphorylation are regulated by the PI3K/AKT/mTOR and Mnk1/2 pathways, respectively. The phosphorylated form of eIF4E drives the expression of oncogenic proteins including those involved in metastasis. This article will review the role of eIF4E in cancer, its regulation, and discuss the benefit of dual-inhibition of upstream pathways. The discernible interplay between the Mnk1/2 and mTOR signaling pathways provides a novel therapeutic opportunity to target aggressive migratory cancers through the development of hybrid molecules
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
Recommended from our members
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Recommended from our members
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML
LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
- …